||EPS - Basic
||Market Cap (m)
|Pharmaceuticals & Biotechnology
Amryt Pharma Share Discussion Threads
Showing 601 to 622 of 625 messages
|My chart shows a short term uptrend that started in early July. Whether that uptrend continues, or breaks down, will depend on the nature of the news released by AMYT, pottermagic. I'd say the AMYT share price is anticipating good news being released and fairly soon, but I could be wrong.
To my eyes the AMYT chart looks similarly poised to back in July. Even the volume profile looks similar to that back in July. All the share price needs is good news, or the perception of good news, like back in August, to rise towards the upper trend line.|
|That chart is NOT nonsense, pottermagic2310. Of course we need news! Only an idiot would suggest otherwise! The chart indicates the share price is poised to respond upwards to good news.|
|Simple... there is absolutely nothing "exciting" about the share price hovering around 16-18p when they should be up at 24p. That Chart above too... NONSENSE... just draw 2 parallel lines left-to-right, downwards and either side of each of the 2 downward trends to see exactly what has really been happening. There is nothing "exciting" about made-up upwards trends or the share price being down between 16-18p... it's NONSENSE !! We need productivity, positive Development outcomes, Products achieving the next level, bankable Assets... New, News, News !!|
|RUBBISH... These are supposed to be worth around 24p/share !!
What are you talking about?
|In a parallel lines uptrend? Looks like it!
free stock charts from uk.advfn.com|
|RUBBISH... These are supposed to be worth around 24p/share !!|
|a bit of excitement this afternoon|
|Potter another Classic from you
Yesterday you were going to snap up a shed full today u are thinking us pi's are stuffed
What is it to be private punter?|
|Further details on the purchase of Scioderm by Amicus. I skimmed Fiercebiotech and it does not look as though Scioderm had any asset other than the EB candidate (Zorblisa, SD-101), but the $841m price needs qualifying. It was "$229 million in stock and cash along with a promise of up to $618 million more for meeting a slate of milestones.". That still makes Amryt look extremely underpriced.
Another point, "TheStreet notes that Zorblisa failed its Phase IIb study, with a small subgroup of patients in the top dose achieving statistical significance compared to a placebo. That top dose is being taken into the Phase III with the blessing of regulators."
And yet another: I asked what route to market Amryt envisaged for Episalvan, and the answer is they intend to manufacture and distribute it themselves, with subcontractors for bits (packing in tubes & sterilising ... I may not remember the full story here). That is not as high risk as it might sound, because EB will be treated by a small number of specialists, so making contact with the expected market will not be as difficult as with a more general product.
The Fiercebiotech page (if ADVFN don't remove it) is hTTp://www.fiercebiotech.com/financials/amicus-bags-phiii-rare-disease-drug-847m-scioderm-buyout|
|No actual progress of any tangible value at all, on any front, just people getting paid to turn up and play with gloop in a Lab (maybe?). I have some personal experience & insight into Lab R&D and this now feels very, very stale to me. Scientists work with Facts & Figures. Good (or better) results are published, when nobody is publishing the Facts & Figures it's simply because there aren't any or they're poor (or worse!). Right now we have no Product to take to the next level and only aspirations of when something MIGHT become available, maybe. As an Investor I dearly wish for this to work out for the best... but I'm already sensing it's just another vehicle to benefit the Beneficiaries... and that doesn't include us PIs !
|gnnmartin - thanks for the detailed post.|
|Great post - thanks for the comprehensive update. There is a lot in there to digest, particularly for someone like me who has next to no understanding of the pharma market.
Very best wishes.
|One other question for anyone here..
Rory Nealon states that the study will cost about £6 - £7 Million and will take 18 months. In addition, we are currently working to a £500k a month cash burn. Our cash balance is about £10M. That is not going to get us anywhere near 2018 based on those numbers. Have I missed something?
Thanks in advance.
Thanks very much for that. Did they give an update on trials and/or discussions with the regulatory authorities please?
|Nigel thanks for that
I was at the Scancell AGM in Oxford this afternoon and didn't get away until 16.30, so there was no chance of me getting to the Walkie Talkie by 17.30, it sounds like it was a useful meeting. I was quite impressed with Rory Nealon when he presented at the Biotech Capital meeting in August:
|I went to the meeting. Yes they will need to raise money sometime. I think they said they have enough cash to last them to June '18. Only think, because it looks to me as though they will be running tight by Jan 2018. They think they should be able to raise money by (for example) selling the rights to Episalvan in Japan for the treatment of Epidermolysis Bullosa (EB) for an up front plus milestones plus royalty. I expect that they hope the share price might get nearer where they think it should be, then perhaps they would raise cash on the market. That's my assessment, I'm not reporting what was said. Anyhow, sufficient unto the day.
I was impressed by the presentation. I was sorry that Tim was not there to ask more informed questions. One question that had troubled me was whether Episalvan would sell for the same price when treating EB as it does for treating partial wounds, and the answer was yes: the extra revenues come because the daily use by EB sufferers will be many times greater than a partial thickness wounds.
I came away impressed, happy to hold.|
|It is a crazy thing to say
Why not sell your holding and buy back at 14.5p
I rest my case|
|Why ? It's not "tripe" or "classic"(?) if it's what I'm actually thinking about, taking ALL prevailing circumstances into consideration should the share price drop that low in the near future, e.g. next 4 weeks. It's just a simple statement of fact from my personal perspective.|
I have heard some tripe over the years but what a classic private punter quote this is
"" I hope it does get close to 14.5p sometime soon. I will be in for some more at that share price ""|
|"I hope it does get close to 14.5p sometime soon."Probably soon. IMO the presentation is about generating interest. I wonder what for?Smells like a placing, they'll need more cash to get this over the hurdles ahead, and best do it now as market's good and not early next year whilst Brexit is fully underway. My opinion as said. Hope I'm wrong.|
|I am not invested there, but I have been keeping an eye on the Sound Energy board simply because they appear to be having some success with our old asset. I have to say, whilst there's a long way to go and it could fall flat, I am impressed with their board of directors who have kept investors informed of all developments and even organised an investor visit to Tendrara. Furthermore, they appear to reply to every email. Good form that!
Perhaps we will get an update (or news) following the presentation tonight at Shard Capital. Is anyone here going?|
|I hope it does get close to 14.5p sometime soon. I will be in for some more at that SP|